Core Viewpoint - The article discusses the impact of the U.S. tariff policies on global trade and the subsequent response from China, highlighting the opportunities for domestic industries to replace imports in various sectors due to increased tariffs on U.S. goods [1] Group 1: Import Substitution Opportunities - The sectors with significant import substitution potential in A-shares include chips, photoresists, scientific instruments, medical devices, and aerospace equipment [1] - A total of 50 stocks have been identified as having strong potential for import substitution based on performance and institutional interest [1][6] Group 2: High Import Dependency Categories - Key categories with high import dependency in China include electronics (semiconductor components/devices, optical components), medical devices, machinery (measuring instruments, machine tools, cutting tools), aerospace equipment, and chemical products [4] - In 2022, China's imports from the U.S. in electronic machinery, agricultural products, chemicals, and energy exceeded 150 billion yuan, indicating a significant reliance on U.S. imports [5] Group 3: Market Size and Growth Potential - The global market for analog chips is valued at $79.4 billion, with China's demand accounting for 30% to 40%, translating to a market space of approximately 240 billion yuan [6] - The medical device market in China has a high dependency on imports, with 70% of high-end equipment (e.g., MRI, CT machines) sourced from companies like GE and Siemens, representing a market space worth several hundred billion yuan [6] Group 4: R&D Investment and Innovation - The average R&D investment ratio for the top 50 import substitution stocks exceeds 21%, significantly higher than the A-share average [9] - Notable companies include Longxin Technology with an R&D investment ratio of 105.34%, and BeiGene with over 14.1 billion yuan invested in R&D, focusing on innovative cancer treatments [9][10] Group 5: Stock Performance and Growth Projections - Among the top 50 stocks, companies like SMIC, Haiguang Information, and Heng Rui Medicine have market capitalizations exceeding 100 billion yuan, primarily in semiconductor equipment, AI chips, and innovative pharmaceuticals [7] - The average projected net profit growth for these companies is close to 69%, with several stocks expected to double their profits this year [12]

刘闯 SAC：S1350524030002 liuchuang@huayuanstock.com 市场表现： | 基本数据 | 日 | | | | 2025 | 年 | | 29 | 04 | | | 月 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 收盘价（元） | | | | | | | | 103.09 | | | | | | | / 低 | | 最 | 高 | 最 | | | 年 | | | 内 | | | 一 | | （元） | | | | | | | | 109.89/49.00 | | | | | | | 总市值（百万元） | | | | | | | | 27,288.77 | | | | | | | 流通市值（百万元） | | | | | | | | 27,288.77 | | | | | | | 总股本（百万股） | | | | | | | | 264.71 | | | | | | | 资产负债率（%） | | | | | | | | 58.06 | | ...

Group 1: Shanghai Jahwa - Shanghai Jahwa is confident about achieving high double-digit GMV growth for its core brands during the 618 shopping festival [1] - The employee stock ownership plan aims to enhance competitiveness, reduce turnover rates, and foster a sense of ownership among employees [1] - The company has made strategic adjustments in the past six months, including organizational design, talent development, and cultural initiatives [1] - E-commerce strategies have been refined, including inventory management, pricing adjustments, organizational restructuring, and product iterations [1] - The Yuze B5 series is planned to be a key product line on JD.com [1] - The company aims for double-digit revenue growth this year and to turn profits around [1] - The long-term profit recovery is expected to follow a timeline of 1-2 years for revenue growth, 2-3 years for profit improvement, and 3-5 years to meet profit margin targets [1] - The main brand Yuze is positioned as a skin barrier repair expert, while Liushen is expanding its usage scenarios and target demographics [1] Group 2: Zai Lab - Zai Lab introduced its pipeline drugs ZG006, ZG005, and ZGGS18, highlighting their latest developments and future plans for the next 3-5 years [2] - ZG006 is the world's first DLL3-expressing tumor tri-specific antibody, which has received clinical trial approvals from NMPA and FDA, showing promising early efficacy [2] - ZG005 is one of the first drugs in clinical research targeting the same pathway, with multiple clinical studies underway [2] - ZGGS18 has completed the dose escalation in Phase I trials in China and is currently in Phase I/II clinical trials [2] - The company plans to continuously explore the commercialization potential of its existing and upcoming products to achieve sustained revenue growth [2] - Zai Lab also discussed the sales progress and future expectations for recombinant human thrombin and the approval status of recombinant human thyroid-stimulating hormone [2] Group 3: Company Overview - Shenzhen Zhongou Ruibo Investment Management Co., Ltd. was established in 2007 and is one of the earliest private equity fund management companies in China [3] - The company focuses on secondary market securities investment and has launched over 50 private equity products in collaboration with top domestic financial institutions [3] - It obtained private fund manager qualifications in 2014 and launched its first overseas fund in 2016 [3] - The name "Rabbit Fund" reflects the company's investment culture of risk management, emphasizing the importance of risk prevention and management [3] - The investment philosophy is centered on growing alongside great companies and adapting strategies to respect market trends [3] - The company has received numerous accolades for its performance, including the "Morningstar Award" and "Golden Bull Award" [3]

Group 1: ZaiJing Pharmaceutical - ZaiJing Pharmaceutical introduced its pipeline drugs ZG006, ZG005, and ZGGS18, with ZG006 being the world's first DLL3 expressing tumor tri-specific antibody approved for clinical trials by NMPA and FDA, showing promising early efficacy [1] - The company plans to explore the commercialization potential of its existing and upcoming products over the next 3-5 years to achieve continuous revenue growth [1] - Sales progress of recombinant human thrombin and the approval status of recombinant human thyroid-stimulating hormone were also discussed [1] Group 2: TianenKang - TianenKang's CKB ointment for vitiligo has completed enrollment of 200 subjects in Phase II clinical trials, with results expected in July 2025 [2] - The company has received acceptance for the domestic production registration of its Hewei Zhengchang Wan and aims for approval within the year [2] - Multiple product approvals are planned within the next year, including CKB and injectable paclitaxel polymer micelles [2] Group 3: Ailis - Ailis discussed the progress of key products, including the completion of multiple reviews for Goleirese tablets, which are entering comprehensive review stages [3] - The company plans to submit an NDA for the registration clinical study of a second-line treatment for 20 exon insertion mutations this year [3] - Ailis aims to expand its sales team and optimize resource allocation to ensure stable operations, with a cash dividend of 292.5 million yuan planned for 2024 [3] Group 4: Jingrui Electric Materials - Jingrui Electric Materials reported a 27.61% year-on-year revenue increase in photolithography glue, reaching 198 million yuan, driven by downstream recovery and domestic substitution [4] - The company’s high-purity sulfuric acid sales revenue nearly doubled, with a threefold increase in sales volume [4] - Plans to acquire 76.0951% of Hubei Jingrui's shares have been approved by the board [4] Group 5: Xinjie Electric - Xinjie Electric's gross margin increased by 2% in 2024, with plans to maintain stability through cost optimization [5] - The company is expanding its PLC products across various industries and is actively developing humanoid robot components [5] - Xinjie Electric plans to increase its dividend payout significantly and aims to boost sales in Southeast Asia, India, and the Middle East [5] Group 6: Institutional Overview - Shenzhen Zhengyuan Investment, established in 2015, focuses on serving the development of China's real economy through professional investment research capabilities [6] - The firm aims to connect social capital with quality industries, facilitating asset allocation to companies aligned with development trends [6]

Group 1: Shanghai Jahwa - Shanghai Jahwa is confident about achieving high double-digit GMV growth for its core brands during the 618 shopping festival [1] - The employee stock ownership plan aims to enhance competitiveness, reduce turnover, and foster a sense of ownership among employees [1] - Recent strategic adjustments include clarifying strategy, aligning organizational design, building talent teams, and cultural development [1] - E-commerce initiatives involve inventory optimization, pricing adjustments, organizational restructuring, and product iteration [1] - The Yuze B5 series is planned as a key product line for JD.com [1] - The company aims for double-digit revenue growth this year and to turn profits around [1] - The long-term profit recovery is expected to follow a 1-2 year revenue growth, 2-3 year profit improvement, and 3-5 year profit margin targets [1] Group 2: Zai Lab - Zai Lab introduced its pipeline drugs ZG006, ZG005, and ZGGS18, highlighting their latest progress and future plans for R&D, commercialization, and internationalization over the next 3-5 years [2] - ZG006 is the world's first DLL3-expressing tumor tri-specific antibody, which has received clinical trial approval from NMPA and FDA, showing promising early efficacy [2] - ZG005 is among the first drugs in clinical research targeting the same pathway, with multiple clinical studies ongoing [2] - ZGGS18 has completed the I phase dose escalation in China and is currently in I/II phase clinical trials [2] - The company plans to continuously explore the commercialization potential of its existing and upcoming products to achieve sustained revenue growth [2] Group 3: Aladdin - Aladdin has achieved several domestic product replacements through independent R&D and innovation, enhancing its competitive edge [3] - The company collaborates with Yuan Ye and Fei Peng to share resources, expand business scale, and improve overall competitiveness [3] - Cost control measures include promoting convertible bond conversions, optimizing inventory turnover, and expanding overseas markets and biological reagent business [3] - Revenue growth in the life sciences sector is primarily driven by the merger with Yuan Ye Bio, increasing sales of major life science products [3] - Both external and internal growth strategies are driving the company's development, with active research into potential acquisition projects [3] Group 4: Company Overview - Shanghai Licheng Asset is one of the earliest established private equity management companies in China, focusing on growth stock investment with a safety margin approach [4] - The company has a complete and unique investment management knowledge system, with a team of 50 employees, nearly 30 of whom are professional research analysts [4] - The management scale has exceeded 10 billion yuan, specializing in secondary stock long strategies and PIPE strategies in the pharmaceutical, advanced manufacturing, and consumer sectors [4] - Licheng has consistently ranked high in long-term performance and has received multiple private equity awards [4]

Core Viewpoint - The article highlights the journey of Sheng Zelin, the founder of ZaiJing Pharmaceutical, who established the company at the age of 49 and has faced significant challenges despite recent stock price increases and revenue growth. The company has been criticized for its declining R&D investment and increasing sales expenses, raising concerns about its future in the competitive pharmaceutical industry [2][12][18]. Company Overview - Sheng Zelin founded ZaiJing Pharmaceutical in 2009, and it became the first "three-no" (no products, no revenue, no profit) company to be listed on the Sci-Tech Innovation Board in 2020 [2][10]. - The company's stock price has doubled in the past year, with a market capitalization of 26.68 billion yuan and Sheng Zelin's wealth exceeding 5 billion yuan [2][10]. - Despite achieving over 500 million yuan in revenue in 2024, the company has accumulated losses of approximately 2.8 billion yuan from 2016 to 2024 [2][12][13]. Financial Performance - In 2024, ZaiJing Pharmaceutical reported a revenue of 533 million yuan, a year-on-year increase of 37.91%, but still recorded a net loss of 138 million yuan [12][18]. - The company has faced continuous losses since 2016, with cumulative losses reaching 2.8 billion yuan by 2024 [12][13]. R&D and Sales Strategy - ZaiJing Pharmaceutical has seen a significant reduction in R&D investment, with R&D expenses decreasing from 509 million yuan in 2021 to 388 million yuan in 2024, while sales expenses have consistently exceeded half of the annual revenue [25][18]. - The number of R&D personnel has also declined, from 324 in 2022 to 289 in 2024, indicating a shift in focus towards marketing rather than innovation [25][18]. Market Position and Challenges - The company successfully launched its core product, Donafenib, in 2021, which broke the long-standing monopoly of Bayer's drug in the liver cancer market [10][24]. - However, ZaiJing Pharmaceutical missed critical market opportunities due to delays in product launches and is now facing intense competition from generics and other innovative therapies [20][25]. - The reliance on capital infusion for operations raises concerns about the sustainability of the business model, especially with increasing marketing costs and decreasing R&D efforts [18][15].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688266 证券简称：泽璟制药 公告编号：2025-018 苏州泽璟生物制药股份有限公司 关于参加 2024 年度科创板创新药行业 集体业绩说明会的公告 ● 投资者可于 2025 年 4 月 28 日（星期一）至 5 月 7 日（星期三）16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 zelgen01@zelgen.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 重要内容提示： 苏州泽璟生物制药股份有限公司（以下简称"公司"）已于 2025 年 4 月 19 日 发布公司 2024 年年度报告，为便于广大投资者更全面深入地了解公司 2024 年度 经营成果、财务状况，公司拟参加由上海证券交易所主办的 2024 年度科创板创 新药行业集体业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2024 年度的经营成果 及财务指标的具体情况与投资者进行互动交流和沟通， ...

医药生物/化学制药 泽璟制药（688266.SH） 营收同比稳健增长，早研管线展现 BIC 潜力 2025 年 04 月 23 日 投资评级：买入（维持） | 日期 | 2025/4/22 | | --- | --- | | 当前股价(元) | 107.60 | | 一年最高最低(元) | 109.89/45.30 | | 总市值(亿元) | 284.83 | | 流通市值(亿元) | 284.83 | | 总股本(亿股) | 2.65 | | 流通股本(亿股) | 2.65 | | 近 3 个月换手率(%) | 68.4 | 股价走势图 数据来源：聚源 -40% 0% 40% 80% 120% 160% 2024-04 2024-08 2024-12 2025-04 泽璟制药 沪深300 相关研究报告 《Q3 收入端环比持续增长，早研创新 进入收获期—公司信息更新报告》 -2024.10.28 公司后期管线稳步推进，大单品吉卡昔替尼针对骨髓纤维化适应症已申报 NDA， 预计 2025H1 获批。早期管线中，ZG006（CD3×DLL3×DLL3 三抗）在 I 期临 床中展现出优异的抗肿瘤疗效，尤其在 10m ...

公司报告 | 公司点评 泽璟制药（688266） 证券研究报告 业绩增长符合预期，在研品种将在 ASCO 会议披露数据 事件 公司公布 2024 年年度报告和 2025 年第一季度报告。2024 年，公司实现营 业收入 5.33 亿元，同比增长 37.91%；归母净利润为-1.38 亿元，同比减亏 50.52%。2025 年第一季度，公司实现营业收入 1.68 亿元，同比增长 54.87%； 归母净利润为-2826.22 万元，同比减亏 28.45%。 在研项目 ZG006 初步有效性数据超预期，预计 ASCO 将更新数据 ZG006 在晚期小细胞肺癌或神经内分泌癌患者中 I 期剂量递增阶段已完成 入组。已经完成的爬坡剂量组分别为 0.1、0.3、1、3、10、30、60 mg 组， 可评估 24 例受试者，其中大多数受试者（17/24）既往曾接受过至少两线 抗肿瘤药物系统治疗。有效性方面，在 21 例疗效可评估的小细胞肺癌 （SCLC）受试者中，7 例获得部分缓解（PR），5 例疾病稳定（SD）且其中 4 例为缩小的 SD。在接受 ZG006 10mg 及更高剂量的 9 例 SCLC 受试者 中（10 mg ...

医药生物/化学制药 泽璟制药（688266.SH） 营收同比稳健增长，早研管线展现 BIC 潜力 2025 年 04 月 23 日 投资评级：买入（维持） | 日期 | 2025/4/22 | | --- | --- | | 当前股价(元) | 107.60 | | 一年最高最低(元) | 109.89/45.30 | | 总市值(亿元) | 284.83 | | 流通市值(亿元) | 284.83 | | 总股本(亿股) | 2.65 | | 流通股本(亿股) | 2.65 | | 近 3 个月换手率(%) | 68.4 | 股价走势图 数据来源：聚源 -40% 0% 40% 80% 120% 160% 2024-04 2024-08 2024-12 2025-04 泽璟制药 沪深300 相关研究报告 《Q3 收入端环比持续增长，早研创新 进入收获期—公司信息更新报告》 -2024.10.28 《营收环比稳健增长，持续增强早研 管线布局能力—公司信息更新报告》 -2024.8.25 《国内 biotech 领航者，即将步入创新 药密集收获期—公司首次覆盖报告》 -2024.7.2 | 余汝意（分析师） | ...